AbbVie Submits Atogepant for Acute Migraine Treatment Review to European Medicines Agency

-1.15%

AbbVie, Inc.

ABBV

214.98

-1.15%

AbbVie Inc. has submitted an application to the European Medicines Agency (EMA) seeking expanded use of atogepant for the acute treatment of adults with migraine across Europe. The submission follows positive results from the pivotal Phase 3 ECLIPSE study, which demonstrated atogepant's superiority over placebo in achieving pain freedom two hours after treatment of the first migraine attack. If approved, atogepant would offer a new acute treatment option for migraine attacks in Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN34050) on December 01, 2025, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.